Browsing Tag
Multiple myeloma
44 posts
Gilead Sciences to double down on CAR T with $7.8bn Arcellx acquisition
Find out how Gilead Sciences’ $7.8 billion Arcellx acquisition reshapes the future of anito-cel and the competitive landscape in multiple myeloma.
What continuous drug exposure could mean for immunomodulatory therapy in multiple myeloma
Can continuous lenalidomide exposure reshape immunomodulatory therapy economics? Explore the strategic stakes for Starton Therapeutics Inc.
CARsgen showcases early clinical results for CT0596 allogeneic BCMA CAR-T cell therapy in multiple myeloma
CARsgen unveils early CT0596 CAR-T trial results at ASH 2025, showing deep responses and strong tolerability in multiple myeloma. See what’s next for the therapy.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Darzalex Faspro moves closer to FDA approval as first therapy for high-risk smoldering multiple myeloma
Find out how Darzalex Faspro could become the first FDA-approved therapy for high-risk smoldering multiple myeloma, reshaping early myeloma care.
Caribou Biosciences set for key webcast showcasing CRISPR-engineered CAR-T breakthroughs in blood cancers
Discover how Caribou Biosciences is preparing to reveal breakthrough CRISPR-edited allogeneic CAR-T data in lymphoma and myeloma during its investor webcast.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
Can immune-based doublets push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can immune-based doublets like TECVAYLI and DARZALEX FASPRO push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can Johnson & Johnson’s TECVAYLI and DARZALEX FASPRO regimen redefine first-line multiple myeloma treatment?
Johnson & Johnson’s TECVAYLI + DARZALEX FASPRO combo hit 100% MRD negativity in new myeloma trial. Can this immune-based regimen redefine frontline care?
Exicure completes Phase 2 trial of GPC-100 for stem cell mobilization in multiple myeloma patients
Exicure (NASDAQ: XCUR) completes final patient visit in Phase 2 GPC-100 trial for stem cell mobilization in multiple myeloma; topline results expected Q4 2025.